{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:53:46Z","timestamp":1791500026280,"version":"4.3.4"},"reference-count":68,"publisher":"Institute of Biochemistry","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BIOMED KHIM"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:p>Fabomotizole is an original anxiolytic agent developed at the Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies that acts on a number of important receptor systems of the brain. In a model of Parkinson's disease induced in rats by a course of rotenone administration, fabomotizole attenuated manifestations of behavioral impairments and influenced the profile and relative content of brain proteins. Five days after the last administration of rotenone, the fabomotizole effect on the behavioral reactions of rats persisted. According to the proteomic study, the profile of brain proteins and changes in their relative content differed significantly from the results obtained immediately after the last administration of rotenone, as well as rotenone in combination with fabomotizole. Changes in the relative content of almost all proteins detected immediately after the last administration of rotenone or rotenone with fabomotizole were not detectable five days later. However, at this time point, there were changes in the relative content of other proteins associated with neurodegeneration in Parkinson's and Alzheimer's diseases. Such dynamics suggests a wave-like change in the content of pathogenetically important brain proteins involved in the mechanisms of neurodegeneration and neuroprotection.<\/jats:p>","DOI":"10.18097\/pbmcr1586","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T16:31:29Z","timestamp":1750869089000},"page":"217-226","source":"Crossref","is-referenced-by-count":1,"title":["The delayed effect of the neuroprotector fabomotizole on the brain proteome in rats with the rotenone model of parkinsonism"],"prefix":"10.18097","volume":"71","author":[{"given":"O.A.","family":"Buneeva","sequence":"first","affiliation":[{"name":"Institute of Biomedical Chemistry, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.G.","family":"Kapitsa","sequence":"additional","affiliation":[{"name":"Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.G.","family":"Zavyalova","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Chemistry, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.A.","family":"Kaloshina","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Chemistry, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.G.","family":"Zgoda","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Chemistry, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.E.","family":"Medvedev","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Chemistry, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7443","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Fleming S.M., Zhu C., Fernagut P.-O., Mehta A., di Carlo C.D., Seaman R.L., Chesselet M.-F. (2004) Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone. Exp. Neurol., 187(2), 418\u2013429.","DOI":"10.1016\/j.expneurol.2004.01.023"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Duty S., Jenner P. (2011) Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br. J. Pharmacol., 164, 1357\u20131391.","DOI":"10.1111\/j.1476-5381.2011.01426.x"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Cannon J.R., Tapias V., Na H.M., Honick A.S., Drolet R.E., Greenamyre J.T. (2009) A highly reproducible rotenone model of Parkinson's disease. Neurobiol. Dis., 34(2), 279\u2013290.","DOI":"10.1016\/j.nbd.2009.01.016"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Kapitsa I.G., Kazieva L.Sh., Vavilov N.E., Zgoda V.G., Kopylov A.T., Medvedev A.E., Buneeva O.A. (2023) Characteristics of behavioral reactions and the profile of brain isatin-binding proteins of rats with the rotenone-induced experimental parkinsonism. Biomeditsinskaya Khimiya, 69(1), 46\u201354.","DOI":"10.18097\/PBMC20236901046"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Buneeva O.A., Kapitsa I.G., Kazieva L.Sh., Vavilov N.E., Zgoda V.G., Medvedev A.E. (2024) The delayed effect of rotenone on the relative content of brain isatin-binding proteins of rats with experimental parkinsonism. Biomeditsinskaya Khimiya, 70(1), 25\u201332.","DOI":"10.18097\/PBMC20247001025"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Buneeva O., Medvedev A. (2025) Monoamine oxidase inhibitors in toxic models of Parkinsonism. Int. J. Mol. Sci., 26(3), 1248.","DOI":"10.3390\/ijms26031248"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Voronin M.V., Kadnikov I.A., Abramova E.V. (2021) Molecular mechanisms of afobazole neurotropic action. Eksperimentalnaya i Klinicheskaya Farmakologiya, 84(2), 15\u201322.","DOI":"10.30906\/0869-2092-2021-84-2-15-22"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Voronin M.V., Vakhitova Y.V., Tsypysheva I.P., Tsypyshev D.O., Rybina I.V., Kurbanov R.D., Abramova E.V., Seredenin S.B. (2021) Involvement of chaperone Sigma1R in the anxiolytic effect of fabomotizole. Int. J. Mol. Sci., 22(11), 5455.","DOI":"10.3390\/ijms22115455"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Mirzoyan R.S., Balasanyan M.G., Topchyan H.V., Hakobyan V.P., Gan'shina T.S., Khaylov N.A., Kurdyumov I.N., Turilova A.I., Antipova \u0422.A., Kraineva V.A., Seredenin S.B. (2022) The cerebrovascular, neuroprotective and antiarrhythmic properties of the anxiolytic fabomotizole. Annals of Clinical and Experimental Neurology, 16(3), 65\u201373.","DOI":"10.54101\/ACEN.2022.3.8"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Buneeva O.A., Kapitsa I.G., Zgoda V.G., Medvedev A.E. (2023) Neuroprotective effects of isatin and afobazole in rats with rotenone-induced parkinsonism are accompanied by increased brain levels of Triton X-100 soluble alpha-synuclein. Biomeditsinskaya Khimiya, 69(5), 290\u2013299.","DOI":"10.18097\/PBMC20236905290"},{"key":"ref11","unstructured":"Voronina T.A., Valdman E.A., Nerobkova L.N., Kapitsa I.G. (2012) In: Rukovodstvo Po Provedeniyu Doklinicheskih Issledovanij Lekarstvennyh Sredstv, Chast' Pervaya (Mironov A.N. (ed.)). Grif i K, Moscow, pp. 219-235."},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Bradford M.M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72, 248\u2013254.","DOI":"10.1016\/0003-2697(76)90527-3"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Buneeva O.A., Kapitsa I.G., Kazieva L.Sh., Vavilov N.E., Zgoda V.G. (2023) Quantitative changes of brain isatin-binding proteins of rats with the rotenone-induced experimental parkinsonism. Biomeditsinskaya Khimiya, 69(3), 188\u2013192.","DOI":"10.18097\/PBMC20236903188"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Arnold S. (2012) Cytochrome c oxidase and its role in neurodegeneration and neuroprotection. Adv. Exp. Med. Biol., 748, 305\u2013339.","DOI":"10.1007\/978-1-4614-3573-0_13"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Agarwal A., Chandran A., Raza F., Ungureanu I.-M., Hilcenko C., Stott K., Bright N.A., Morone N., Warren A.J., Lautenschl\u00e4ger J. (2024) VAMP2 regulates phase separation of \u03b1-synuclein. Nat. Cell Biol., 26(8), 1296\u20131308.","DOI":"10.1038\/s41556-024-01451-6"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Wang C., Zhang K., Cai B., Haller J.E., Carnazza K.E., Hu J., Zhao C., Tian Z., Hu X., Hall D., Qiang J., Hou S., Liu Z., Gu J., Zhang Y., Seroogy K.B., Burre J., Fang Y., Liu C., Brunger A.T., Li D., Diao J. (2024) VAMP2 chaperones \u03b1-synuclein in synaptic vesicle co-condensates. Nat. Cell Biol., 26(8), 1287\u20131295.","DOI":"10.1038\/s41556-024-01456-1"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Laferri\u00e8re F., Claverol S., Bezard E., de Giorgi F., Ichas F. (2022) Similar neuronal imprint and no cross-seeded fibrils in \u03b1-synuclein aggregates from MSA and Parkinson's disease. NPJ Parkinsons Dis., 8, 10.","DOI":"10.1038\/s41531-021-00264-w"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Buneeva O., Medvedev A. (2022) Atypical ubiquitination and Parkinson's disease. Int. J. Mol. Sci., 23(7), 3705.","DOI":"10.3390\/ijms23073705"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Hurley M.J., Brandon B., Gentleman S.M., Dexter D.T. (2013) Parkinson's disease is associated with altered expression of CaV1 channels and calcium-binding proteins. Brain, 136(Pt 7), 2077\u20132097.","DOI":"10.1093\/brain\/awt134"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Zaichick S.V., McGrath K.M., Caraveo G. (2017) The role of Ca2+ signaling in Parkinson's disease. Dis. Model. Mech., 10(5), 519\u2013535.","DOI":"10.1242\/dmm.028738"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Zhong J., Tang G., Zhu J., Wu W., Li G., Lin X., Liang L., Chai C., Zeng Y., Wang F., Luo L., Li J., Chen F., Huang Z., Zhang X., Zhang Y., Liu H., Qiu X., Tang S., Chen D. (2021) Single-cell brain atlas of Parkinson's disease mouse model. J. Genet. Genomics Yi Chuan Xue Bao, 48(4), 277\u2013288.","DOI":"10.1016\/j.jgg.2021.01.003"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Curtis W.M., Seeds W.A., Mattson M.P., Bradshaw P.C. (2022) NADPH and mitochondrial quality control as targets for a circadian-based fasting and exercise therapy for the treatment of Parkinson's disease. Cells, 11(15), 2416.","DOI":"10.3390\/cells11152416"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Favretto F., Baker J.D., Stroh\u00e4ker T., Andreas L.B., Blair L.J., Becker S., Zweckstetter M. (2020) The molecular basis of the interaction of cyclophilin A with \u03b1-synuclein. Angew. Chem. Int. Ed. Engl., 59(14), 5643\u20135646.","DOI":"10.1002\/anie.201914878"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Nakao N., Frodl E.M., Widner H., Carlson E., Eggerding F.A., Epstein C.J., Brundin P. (1995) Overexpressing Cu\/Zn superoxide dismutase enhances survival of transplanted neurons in a rat model of Parkinson's disease. Nat. Med., 1(3), 226\u2013231.","DOI":"10.1038\/nm0395-226"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Choi J., Rees H.D., Weintraub S.T., Levey A.I., Chin L.-S., Li L. (2005) Oxidative modifications and aggregation of Cu,Zn-superoxide dismutase associated with Alzheimer and Parkinson diseases. J. Biol. Chem., 280(12), 11648\u201311655.","DOI":"10.1074\/jbc.M414327200"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Kuang X.-L., Liu F., Chen H., Li Y., Liu Y., Xiao J., Shan G., Li M., Snider B.J., Qu J., Barger S.W., Wu S. (2014) Reductions of the components of the calreticulin\/calnexin quality-control system by proteasome inhibitors and their relevance in a rodent model of Parkinson's disease. J. Neurosci. Res., 92(10), 1319\u20131329.","DOI":"10.1002\/jnr.23413"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Katayama T., Sawada J., Takahashi K., Yahara O., Hasebe N. (2021) Meta-analysis of cerebrospinal fluid neuron-specific enolase levels in Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Alzheimers Res. Ther., 13(1), 163.","DOI":"10.1186\/s13195-021-00907-3"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Villa R.F., Arnaboldi R., Ghigini B., Gorini A. (1992) Mitochondrial factors involved in Parkinson's disease by MPTP toxicity in Macaca fascicularis and drug effect. Neurochem. Res., 17(11), 1147\u20131154.","DOI":"10.1007\/BF00967293"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Keane P.C., Kurzawa M., Blain P.G., Morris C.M. (2011) Mitochondrial dysfunction in Parkinson's disease. Parkinsons Dis., 2011, 716871.","DOI":"10.4061\/2011\/716871"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Xu J., Fu X., Pan M., Zhou X., Chen Z., Wang D., Zhang X., Chen Q., Li Y., Huang X., Liu G., Lu J., Liu Y., Hu Y., Pan S., Wang Q., Wang Q., Xu Y. (2019) Mitochondrial creatine kinase is decreased in the serum of idiopathic Parkinson's disease patients. Aging Dis., 10(3), 601\u2013610.","DOI":"10.14336\/AD.2018.0615"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Poon H.F., Frasier M., Shreve N., Calabrese V., Wolozin B., Butterfield D.A. (2005) Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice \u2014 a model of familial Parkinson's disease. Neurobiol. Dis., 18(3), 492\u2013498.","DOI":"10.1016\/j.nbd.2004.12.009"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Bar-Am O., Yogev-Falach M., Amit T., Sagi Y., Youdim M.B.H. (2004) Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo. J. Neurochem., 89(5), 1119\u20131125.","DOI":"10.1111\/j.1471-4159.2004.02425.x"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Chen Z., Zhang W., Selmi C., Ridgway W.M., Leung P.S.C., Zhang F., Gershwin M.E. (2021) The myristoylated alanine-rich C-kinase substrates (MARCKS): a membrane-anchored mediator of the cell function. Autoimmun. Rev., 20(11), 102942.","DOI":"10.1016\/j.autrev.2021.102942"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Erhardt B., Marcora M.S., Frenkel L., Bochicchio P.A., Bodin D.H., Silva B.A., Far\u00edas M.I., Allo M.\u00c1., H\u00f6cht C., Ferrari C.C., Pitossi F.J., Leal M.C. (2021) Plasma membrane calcium ATPase downregulation in dopaminergic neurons alters cellular physiology and motor behaviour in Drosophila melanogaster. Eur. J. Neurosci., 54(6), 5915\u20135931.","DOI":"10.1111\/ejn.15401"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Pellegrini L., Wetzel A., Grann\u00f3 S., Heaton G., Harvey K. (2016) Back to the tubule: microtubule dynamics in Parkinson's disease. Cell. Mol. Life Sci., 74(3), 409\u2013434.","DOI":"10.1007\/s00018-016-2351-6"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Song J., Yang X., Zhang M., Wang C., Chen L. (2021) Glutamate metabolism in mitochondria is closely related to Alzheimer's disease. J. Alzheimers Dis., 84(2), 557\u2013578.","DOI":"10.3233\/JAD-210595"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Villar-Conde S., Astillero-Lopez V., Gonzalez-Rodriguez M., Saiz-Sanchez D., Martinez-Marcos A., Ubeda-Banon I., Flores-Cuadrado A. (2023) Synaptic involvement of the human amygdala in Parkinson's disease. Mol. Cell. Proteomics, 22(12), 100673.","DOI":"10.1016\/j.mcpro.2023.100673"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Bohush A., Le\u015bniak W., Weis S., Filipek A. (2021) Calmodulin and its binding proteins in Parkinson's disease. Int. J. Mol. Sci., 22(6), 3016.","DOI":"10.3390\/ijms22063016"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Chithra Y., Dey G., Ghose V., Chandramohan V., Gowthami N., Vasudev V., Srinivas Bharath M.M. (2023) Mitochondrial complex I inhibition in dopaminergic neurons causes altered protein profile and protein oxidation: implications for Parkinson's disease. Neurochem. Res., 48(8), 2360\u20132389.","DOI":"10.1007\/s11064-023-03907-x"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Shi M.-M., Shi C.-H., Xu Y.-M. (2017) Rab GTPases: the key players in the molecular pathway of Parkinson's disease. Front. Cell. Neurosci., 11, 81.","DOI":"10.3389\/fncel.2017.00081"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Bellucci A., Longhena F., Spillantini M.G. (2022) The role of Rab proteins in Parkinson's disease synaptopathy. Biomedicines, 10(8), 1941.","DOI":"10.3390\/biomedicines10081941"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Song Q., Meng B., Xu H., Mao Z. (2020) The emerging roles of vacuolar-type ATPase-dependent lysosomal acidification in neurodegenerative diseases. Transl. Neurodegener., 9(1), 17.","DOI":"10.1186\/s40035-020-00196-0"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Remnest\u00e5l J., Just D., Mitsios N., Fredolini C., Mulder J., Schwenk J.M., Uhl\u00e9n M., Kultima K., Ingelsson M., Kilander L., Lannfelt L., Svenningsson P., Nellg\u00e5rd B., Zetterberg H., Blennow K., Nilsson P., H\u00e4ggmark-M\u00e5nberg A. (2016) CSF profiling of the human brain enriched proteome reveals associations of neuromodulin and neurogranin to Alzheimer's disease. Proteomics Clin. Appl., 10(12), 1242\u20131253.","DOI":"10.1002\/prca.201500150"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Piccini P., Weeks R.A., Brooks D.J. (1997) Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Ann. Neurol., 42(5), 720\u2013726.","DOI":"10.1002\/ana.410420508"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Verma A., Ravindranath V. (2019) CaV1.3 L-type calcium channels increase the vulnerability of substantia nigra dopaminergic neurons in MPTP mouse model of Parkinson's disease. Front. Aging Neurosci., 11, 382.","DOI":"10.3389\/fnagi.2019.00382"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Matuskey D., Tinaz S., Wilcox K.C., Naganawa M., Toyonaga T., Dias M., Henry S., Pittman B., Ropchan J., Nabulsi N., Suridjan I., Comley R.A., Huang Y., Finnema S.J., Carson R.E. (2020) Synaptic changes in Parkinson disease assessed with in vivo imaging. Ann. Neurol., 87(3), 329\u2013338.","DOI":"10.1002\/ana.25682"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Agliardi C., Meloni M., Guerini F.R., Zanzottera M., Bolognesi E., Baglio F., Clerici M. (2021) Oligomeric \u03b1-syn and SNARE complex proteins in peripheral extracellular vesicles of neural origin are biomarkers for Parkinson's disease. Neurobiol. Dis., 148, 105185.","DOI":"10.1016\/j.nbd.2020.105185"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"He Y., Nan D., Wang H. (2023) Role of non-receptor-type tyrosine phosphatases in brain-related diseases. Mol. Neurobiol., 60(11), 6530\u20136541.","DOI":"10.1007\/s12035-023-03487-5"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Hwang H., Zhang J., Chung K.A., Leverenz J.B., Zabetian C.P., Peskind E.R., Jankovic J., Su Z., Hancock A.M., Pan C., Montine T.J., Pan S., Nutt J., Albin R., Gearing M., Beyer R.P., Shi M., Zhang J. (2010) Glycoproteomics in neurodegenerative diseases. Mass Spectrom. Rev., 29(1), 79\u2013125.","DOI":"10.1002\/mas.20221"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Birkner K., Loos J., Gollan R., Steffen F., Wasser B., Ruck T., Meuth S.G., Zipp F., Bittner S. (2019) Neuronal ICAM-5 plays a neuroprotective role in progressive neurodegeneration. Front. Neurol., 10, 205.","DOI":"10.3389\/fneur.2019.00205"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Kim K., Lee S.-G., Kegelman T.P., Su Z.-Z., Das S.K., Dash R., Dasgupta S., Barral P.M., Hedvat M., Diaz P., Reed J.C., Stebbins J.L., Pellecchia M., Sarkar D., Fisher P.B. (2011) Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics. J. Cell. Physiol., 226(10), 2484\u20132493.","DOI":"10.1002\/jcp.22609"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Chung D., Shum A., Caraveo G. (2020) GAP-43 BASP1 in axon regeneration: implications for the treatment of neurodegenerative diseases. Front. Cell Dev. Biol., 8, 567537.","DOI":"10.3389\/fcell.2020.567537"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"MacDonald K., Iulianella A. (2022) The actin-cytoskeleton associating protein BASP1 regulates neural progenitor localization in the neural tube. Genesis, 60(1\u20132), e23464.","DOI":"10.1002\/dvg.23464"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Gray M., Nash K.R., Yao Y. (2024) Adenylyl cyclase 2 expression and function in neurological diseases. CNS Neurosci. Ther., 30(7), e14880.","DOI":"10.1111\/cns.14880"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Zhou Z., Chen Q.-Y., Zhuo M., Xu P.-Y. (2024) Inhibition of calcium-stimulated adenylyl cyclase subtype 1 (AC1) for the treatment of pain and anxiety symptoms in Parkinson's disease mice model. Mol. Pain, 20, 17448069241266683.","DOI":"10.1177\/17448069241266683"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Lee Y.M., Park S.H., Shin D.-I., Hwang J.-Y., Park B., Park Y.-J., Lee T.H., Chae H.Z., Jin B.K., Oh T.H., Oh Y.J. (2008) Oxidative modification of peroxiredoxin is associated with drug-induced apoptotic signaling in experimental models of Parkinson disease. J. Biol. Chem., 283(15), 9986\u20139998.","DOI":"10.1074\/jbc.M800426200"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Roede J.R., Hansen J.M., Go Y.-M., Jones D.P. (2011) Maneb and paraquat-mediated neurotoxicity: involvement of peroxiredoxin\/thioredoxin system. Toxicol. Sci., 121(2), 368\u2013375.","DOI":"10.1093\/toxsci\/kfr058"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Santulli C., Bon C., Cecco E.D., Codrich M., Narkiewicz J., Parisse P., Perissinotto F., Santoro C., Persichetti F., Legname G., Espinoza S., Gustincich S. (2022) Neuronal haemoglobin induces loss of dopaminergic neurons in mouse substantia nigra, cognitive deficits and cleavage of endogenous \u03b1-synuclein. Cell Death Dis., 13(12), 1048.","DOI":"10.1038\/s41419-022-05489-y"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Lin J., Ou R., Li C., Hou Y., Zhang L., Wei Q., Pang D., Liu K., Jiang Q., Yang T., Xiao Y., Zhao B., Chen X., Song W., Yang J., Wu Y., Shang H. (2023) Plasma glial fibrillary acidic protein as a biomarker of disease progression in Parkinson's disease: a prospective cohort study. BMC Med., 21(1), 420.","DOI":"10.1186\/s12916-023-03120-1"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Lape\u00f1a-Luz\u00f3n T., Rodr\u00edguez L.R., Beltran-Beltran V., Benet\u00f3 N., Pallard\u00f3 F.V., Gonzalez-Cabo P. (2021) Cofilin and neurodegeneration: new functions for an old but gold protein. Brain Sci., 11(7), 954.","DOI":"10.3390\/brainsci11070954"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Liu K., Li F., Han H., Chen Y., Mao Z., Luo J., Zhao Y., Zheng B., Gu W., Zhao W. (2016) Parkin regulates the activity of pyruvate kinase M2. J. Biol. Chem., 291(19), 10307\u201310317.","DOI":"10.1074\/jbc.M115.703066"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Williams E.T., Chen X., Moore D.J. (2017) VPS35, the retromer complex and Parkinson's disease. J. Parkinsons Dis., 7(2), 219\u2013233.","DOI":"10.3233\/JPD-161020"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Sassone J., Reale C., Dati G., Regoni M., Pellecchia M.T., Garavaglia B. (2021) The role of VPS35 in the pathobiology of Parkinson's disease. Cell. Mol. Neurobiol., 41(2), 199\u2013227.","DOI":"10.1007\/s10571-020-00849-8"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Schmidt S.I., Blaabjerg M., Freude K., Meyer M. (2022) RhoA signaling in neurodegenerative diseases. Cells, 11(9), 1520.","DOI":"10.3390\/cells11091520"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Le\u00f3n A., Aparicio G.I., Scorticati C. (2021) Neuronal glycoprotein M6a: an emerging molecule in chemical synapse formation and dysfunction. Front. Synaptic Neurosci., 13, 661681.","DOI":"10.3389\/fnsyn.2021.661681"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Chalorak P., Dharmasaroja P., Meemon K. (2020) Downregulation of eEF1A\/EFT3-4 enhances dopaminergic neurodegeneration after 6-OHDA exposure in C. elegans. Model. Front. Neurosci., 14, 303.","DOI":"10.3389\/fnins.2020.00303"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Ren Y., Zhao J., Feng J. (2003) Parkin binds to alpha\/beta tubulin and increases their ubiquitination and degradation. J. Neurosci., 23(8), 3316\u20133324.","DOI":"10.1523\/JNEUROSCI.23-08-03316.2003"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Mazzetti S., Giampietro F., Calogero A.M., Isilgan H.B., Gagliardi G., Rolando C., Cantele F., Ascagni M., Bramerio M., Giaccone G., Isaias I.U., Pezzoli G., Cappelletti G. (2024) Linking acetylated \u03b1-tubulin redistribution to \u03b1-synuclein pathology in brain of Parkinson's disease patients. NPJ Parkinsons Dis., 10, 2.","DOI":"10.1038\/s41531-023-00607-9"}],"container-title":["Biomeditsinskaya Khimiya"],"original-title":[],"language":"ru","deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T16:31:59Z","timestamp":1750869119000},"score":1,"resource":{"primary":{"URL":"http:\/\/pbmc.ibmc.msk.ru\/en\/article-en\/PBMC-2025-71-3-217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":68,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025]]},"published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.18097\/pbmcr1586","relation":{},"ISSN":["2310-6905","2310-6972"],"issn-type":[{"value":"2310-6905","type":"electronic"},{"value":"2310-6972","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}